Portrait de Mikel Orobengoa

Organización: 

ISEA

Europe's wind capacity to grow more slowly than expected to 2020

Europe's installed wind capacity will increase at a slower rate to the end of the decade than previously estimated, due to regulatory uncertainty and weak economic growth, an industry association said on Wednesday (23 July).

European Union countries will have a combined 192.4 gigawatts (GW) of installed wind energy capacity by 2020, 64% higher than 2013 levels, the European Wind Energy Association (EWEA) said in a report.

Learning From the Crowd: The Hardware Ecosystem.

n the past six years crowdfunding has become a popular, if not the most popular, form of financing for hardware startups, potato salad distractions notwithstanding. Over the years we’ve seen a variety of successful crowdfunding campaigns translate early crowd love into great venture capital rounds. We’ve even seen a few, like Oculus, manage to use successful campaigns to catalyze massive exits.

Can Technology Fix Medicine?

After decades as a technological laggard, medicine has entered its data age. Mobile technologies, sensors, genome sequencing, and advances in analytic software now make it possible to capture vast amounts of information about our individual makeup and the environment around us. The sum of this information could transform medicine, turning a field aimed at treating the average patient into one that’s customized to each person while shifting more control and responsibility from doctors to patients.

The question is: can big data make health care better?

MobileOCT: The Incredible Social Startup That Uses Mobile Phones To Detect Cervical Cancer In Third-World Women.

In 95 percent of cases, cervical cancer is an entirely treatable disease and can be treated for $28 in less than 40 minutes. Yet, due to lack of access to physicians and reliable medical equipment, hundreds of thousands of women in low-resource settings are dying unnecessarily every year simply because they are not getting diagnosed in time. However, one Israeli startup seems to be well on its way to changing that.

Meet MobileOCT— a social startup which is using mobile phones to accurately detect cancer in people who live in the developing world.

Airware Preps Launch Of Its Commercial Drone Operating System With $25M From Kleiner.

Building a drone’s hardware and software from scratch is tough and expensive, but open source drone kits are inflexible. So to power businesses looking to customize drones for commercial uses from agriculture to industrial inspections, Airware has raised a $25 million Series B led by Kleiner Perkins. The money will fund the launch of Airware’s drone operating system later this year, including autopilot hardware, navigation, software, and cloud infrastructure for storing and analyzing data from a drone’s sensors.

Eroskik supermerkatu bat ireki du Zumaian.

Tokiko janari fresko mota asko izango da saltokian. Horretaz gain, ogia egiteko labe propioa izango du; horrela, okindegi produktu freskoak bermatuko dira egunero; gainera, urdaitegian, langile bat egongo da.

EROSKI/city bereizgarridun frankizia supermerkatua inauguratu du EROSKIk Zumaian (Gipuzkoa), Ardantzabide kaleko bederatzigarrenean. 290 metro koadro ditu, eta ekoizle liderretako, marka propioko eta tokiko 3.500 produktu sorta izango ditu. Saltokia irekita, lau lanpostu sortu dira.

Synlogic Gets $30M From Atlas, NEA to Turn Smart Bugs Into Drugs.

Synthetic biology has become something of a biotech buzz-phrase—lots of lab experiments and hype, yet little tangible impact on patients to show for it.

Still, new ideas keep coming out of the startup world to finally harness the potential that comes with genetically engineering biological parts and systems, with the promise of making a huge difference in healthcare. Today, one of those ambitious ideas is taking shape in a Cambridge, MA-based startup called Synlogic, which aims to whip up a line of custom-made bacteria that double as little drug-making factories.

Un test pour évaluer le risque de cancer du poumon.

Le tabagisme reste le premier facteur de risque de développement du cancer du poumon. Toutefois, 85% des fumeurs ne développeront jamais de cancer. Le risque est en effet inégalement réparti entre les individus. D'où l'intérêt d'un test permettant d'évaluer le risque individuel. Les chercheurs de l'Institut Weizmann ont mis au point un tel test, basé sur trois marqueurs biologiques [1] et qui exploite la corrélation entre capacité de réparation de l'ADN et probabilité de développer un cancer.
 

Suivi

This person isn't following anyone.